个人简历
教育背景
2018.01-2020.04 美国UT.MD安德森癌症中心 博士后
2014.09-2017.07 复旦大学 理学博士
2011.09-2012.07 浙江大学 博士在读
2008.09-2011.07 哈尔滨医科大学 理学硕士
工作经历
2020.05-今 上海中医药大学中药研究所 研究员,博士生导师
2018.01-2020.04 美国UT.MD安德森癌症中心 博士后
2012.07-2017.09 江南大学附属医院助理研究员
研究兴趣
以满足临床未满足之需求为研究目标,基于消化道肿瘤大样本多组学分析进行药物靶点开发,阐明其分子机制,为抗肿瘤药物靶向性研究奠定基础。积极探索基于非编码RNA开展药物作用靶点发现研究,并基于相应的RNA分子靶点进行抗肿瘤新药研究。
个人荣誉
2020年度上海市浦江学者;第十二批上海市领军人才(海外)青年项目。
获奖情况
江苏省新医学技术引进奖一等奖1项(2016,名列第3位)
代表性论文
15. M Chen, C Li, J Zhang, X Cui, W Tian, P Liao, Q Wang, J Sun, L Luo, H Wu, Y Li. Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study. JMIR Public health and surveillance.2023.
14. T Feng, Y Li, F Ma, E Wu, Z Cheng, S Zhou,Z Wang, L Yang, XSun, J Zhang. Ft1 inhibits colorectal cancer growth by increasing CD8+ T cell proportion in tumor-bearing mice through the USP9X signaling pathway. Chinese Journal of Natural Medicines.2023.
13. A Xiong, J Zhang, Yan Chen, Yi Zhang, Fan Yang. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine. 2022.
12.J Zhang, T Pan, W Zhou, Y Zhang, G Xu, Q Xu, S Li, Y Gao, Z Wang, J Xu, Yongsheng Li. Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022.
11.J Zhang, S Li, J Zhang, W Zhang, J Jiang, H Wu, E Wu, Y Feng, LYang, Z Li. Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway. Cancer Letters. 2022.
10. J Zhao, J Zhang, Q Liu, Y Wang, Y Jin, Y Yang, C Ni, L Zhang. Hongjingtian injection protects against myocardial ischemia reperfusion-induced apoptosis by blocking ROS induced autophagic- flux. Biomed Pharmacother. 2021.
9. Yang Jiao#, Jialiang Zhou#, Mingxu Song, Ling Zhang, Jiayan Zhou*, Jiwei Zhang*. Long non-coding RNA TDRKH-AS1 promotes colorectal cancer cell proliferation and invasion through the β-catenin activated Wnt signaling pathway. Frontiers in Oncology. 2020.
8. J Xu#*, T Shao#, M Song#, Y Xie, J Zhou, J Yin, Na Ding, H Zou, Y Li*, J Zhang*. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Molecular Cancer.2020.
7. J Zhang#*, S Li#, L Zhang#, J Xu, M Song, T Shao, Z Huang, Y Li. Integrative analyses reveal EIF2S2-LINC01600-MYC axis suppresses the regulation of FHIT enhancer to Wnt signaling pathway in gastrointestinal cancer. Molecular Therapy. 2020.
6. S Shen#, J Wang#, Y Shao, Y Tao, M Li, Y Wang, X Ni, T Suo, H Liu*, Han Liu*, J Zhang*. The LINC01714 acts as a tumor suppressor in cholangiocarcinoma by interacting with FOXO3. Molecular Therapy-Nucleic Acids,2020.
5. Z Bian#, J Zhang#, M Li, Y Feng, X Wang, J Zhang, S Yao, G Jin, J Du,Z Huang*. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clinical Cancer Research. 2018.
4. J Zhang#, Z Li#, Liu L#, Wang Q, Li S, Chen D, Hu Z, Yu T, Ding J, Li J, Yao M, Huang S, Zhao Y*, He X*. Long Noncoding RNA TSLNC8 Is a Tumor Suppressor that Inactivates the IL6/STAT3 Signaling Pathway. Hepatology. 2018.
3. Li Z#, J Zhang#, L L#, W Q, Li S, Chen D, Hu Z, Yu T, Ding J, Li J, Yao M, Huang S, Zhao Y*, He X*. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nature Communications. 2018.
2. S Li, J Zhang, S Huang, X He*. Genome-wide analysis reveals that exon methylation facilitates its selective usage in the human transcriptome. Briefings in Bioinformatics. 2017.
1. J Zhang#, Z Bian#, J Zhou, M Song, Z Liu, Y Feng, Z Li, B Zhang, Y Yin, Z Huang*. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein & cell. 2016.
授权专利
无
科研项目
1:长链非编码RNA—MIR22HG通过调控SMAD2抑制结直肠癌生长与转移的分子机制研究(项目批准号:81602033)、国家自然科学基金、17万元、起止日期:2017.01-2019.12,、结题、主持
2:EIF2S2通过STAT3/CD155/TIGIT轴促进结直肠癌免疫逃逸的机制研究(项目批准号:20PJ1413000)、上海市浦江人才、30万元、起止日期:2020.10-2022.9,、结题、主持
3:RNA结合蛋白EIF2S2通过STAT3/CD155轴促进结直肠癌免疫逃逸分子机制研究(项目批准号:82173106)、国家自然科学基金面上项目、55万元、起止日期:2022.01-2025.12,、在研、主持;
4:基于质量源于设计理念的“同方异制”生脉、复方丹参方质量评价新策略(项目批准号:82130115)、国家自然科学基金重点项目、290万元、起止日期:2022.01-2026.12,、骨干参与。
学术任职
兼任Frontiers in Pharmacology 客座主编,《中医药文化》青年编委。
课题组成员